Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases
Open Access
- 25 September 2007
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 97 (8) , 1035-1039
Abstract
We have previously reported that neoadjuvant therapy with modified FOLFIRI enabled nearly a third of patients with metastatic colorectal cancer (mCRC) to undergo surgical resection of liver metastases. Here, we present data from the long-term follow-up of these patients. Forty patients received modified FOLFIRI: irinotecan 180 mg m−2, day 1; folinic acid, 200 mg m−2; and 5-fluorouracil: as a 400 mg m−2 bolus, days 1 and 2, and a 48-h continuous infusion 1200 mg m−2, from day 1. Treatment was repeated every 2 weeks, with response assessed every six cycles. Resected patients received six further cycles of chemotherapy postoperatively. Nineteen (47.5%) of 40 patients achieved an objective response; 13 (33%) underwent resection. After a median follow-up of 56 months, median survival for all patients was 31.5 months: for non-resected patients, median survival was 24 months and was not reached for resected patients. Median time to progression was 14.3 and 5.2 months for all and non-resected patients, respectively. Median disease-free (DF) survival in resected patients was 52.5 months. At 2 years, all patients were alive (8 DF), and at last follow-up, eight were alive (6 DF). Surgical resection of liver metastases after neoadjuvant treatment with modified FOLFIRI in CRC patients achieved favourable survival times.Keywords
This publication has 31 references indexed in Scilit:
- Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver MetastasesAnnals of Surgery, 2006
- Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal CancerAnnals of Surgical Oncology, 2006
- Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinomaAnnals of Oncology, 2005
- Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986Journal of Clinical Oncology, 2005
- Effect of Surgical Margin Status on Survival and Site of Recurrence After Hepatic Resection for Colorectal MetastasesAnnals of Surgery, 2005
- ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of advanced colorectal cancerAnnals of Oncology, 2005
- Tumor Progression While on ChemotherapyAnnals of Surgery, 2004
- Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by ChemotherapyAnnals of Surgery, 2004
- Five-Year Survival After Resection of Hepatic Metastases From Colorectal Cancer in Patients Screened by Positron Emission Tomography With F-18 Fluorodeoxyglucose (FDG-PET)Annals of Surgery, 2004
- Resection of Nonresectable Liver Metastases from Colorectal Cancer After Neoadjuvant ChemotherapyAnnals of Surgery, 1996